WBA Walgreens Boots Alliance (NASDAQ) $11.98 09 Feb 2026: Heavy intraday volume may signal repositioning

WBA stock is trading at $11.98 on the NASDAQ in the United States on 09 Feb 2026, with an unusually large intraday print of 452,081,061 shares that makes it one of today’s most active issues. The share price is up 0.50% from the prior close of $11.92, trading between $11.98 and $11.98 on the session. Investors are watching liquidity and short-interest commentary while valuing Walgreens Boots Alliance, Inc. (WBA) against a 52-week range of $8.08–$13.25. This piece gives an intraday, data-driven take on WBA stock, linking fundamentals, technicals and analyst context for trading and portfolio decisions.

WBA stock intraday snapshot

WBA stock is the market’s most active name today by volume, with 452,081,061 shares trading versus an average volume of 16,940,296, a relative volume of 26.69x. Market cap stands near $10.37 billion (USD) and the stock opened at $11.98. Year high is $13.25 and year low is $8.08, so intraday activity is concentrated in a narrow price band but with extreme turnover.

Why WBA stock moved today

The surge in trading reflects two drivers: heightened retail interest and recent commentary on delisting risk noted in market headlines. Short-interest and price-target notes from MarketBeat set a backdrop; MarketBeat’s forecast page lists a current price target of $9.00. MarketBeat forecast shows mixed analyst positioning, which can amplify intraday swings. High turnover with limited price range suggests traders are repositioning rather than establishing new long-term bets.

WBA stock valuation and financials

Walgreens Boots Alliance, Inc. reports trailing metrics that keep valuation debates active. Price-to-sales is near 0.07, price-to-book is 1.44, and enterprise value to sales is 0.25. Trailing EPS is -7.29, yielding a negative PE of -1.64. The company shows free cash flow per share of 0.67 and book value per share of 8.46. High leverage metrics include debt-to-equity of 4.04 and enterprise value of $38.64 billion, so balance-sheet risk is a core valuation driver.

WBA stock technicals and trading metrics

Technicals show a tight intraday range and extreme volume. Relative Strength Index reads 100.00, flagged as overbought in this snapshot, while ADX at 50.00 signals a strong trend on the high-volume move. The 50-day average price is $11.66 and the 200-day average is $10.81, both below the current price. On-chain indicators for today include on-balance volume at 452,081,061 matching reported turnover.

Analyst consensus, sector context and Meyka grade

Analyst coverage is thin and mixed: MarketBeat records one Hold and two Sell ratings in recent consensus data. The healthcare retail sector shows steady consumer demand but margin pressure from pharmacy reimbursements. Meyka AI rates WBA with a score out of 100: 61.94 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are informational and not financial advice.

WBA stock outlook and risks

Primary near-term catalysts include quarterly results, pharmacy reimbursement updates, and any formal notices on listing status. Key risks are continued negative EPS, high debt-to-equity and weak interest coverage. Opportunities include cost savings from store optimization and international performance stabilization. For historical trading context, see Investing.com price history. Investing.com WBA historical data.

Final Thoughts

WBA stock’s intraday profile on 09 Feb 2026 is defined by massive volume (452,081,061 shares) paired with a stable price near $11.98, a pattern consistent with heavy repositioning rather than clear directional conviction. Valuation remains contested: cheap on price-to-sales but stressed by negative EPS (-7.29) and high debt metrics (debt-to-equity 4.04). Analyst coverage is limited and leans cautious; MarketBeat lists a $9.00 target. Meyka AI’s forecast model projects WBA stock at $14.50 over 12 months, implying an upside of 21.03% from $11.98. Forecasts are model-based projections and not guarantees. Traders focused on most-active names should watch intraday liquidity, short-interest flows, and any regulatory or listing updates. For investors, the stock may merit HOLD exposure sized to risk tolerance given balance-sheet concerns and potential upside if pharmacy margins improve. Meyka AI, an AI-powered market analysis platform, flags WBA as data-rich but headline-sensitive—active traders will find volatility and liquidity; long-term investors should weigh debt reduction and profit recovery as primary catalysts.

FAQs

What drove WBA stock’s large intraday volume today?

Large intraday volume of 452,081,061 shares reflects heavy retail and institutional repositioning plus headlines around listing status and analyst notes. The price stayed near $11.98, indicating turnover over directional conviction.

How does valuation look for WBA stock?

Valuation is mixed: price-to-sales 0.07 and price-to-book 1.44 look inexpensive, but negative EPS (-7.29) and high debt-to-equity (4.04) raise fundamental risks for investors.

What is Meyka AI’s view and rating on WBA stock?

Meyka AI rates WBA with a score out of 100: 61.94 (Grade B, Suggestion HOLD). The grade balances benchmark and sector comparisons, financial growth, key metrics, and analyst consensus.

What price should traders watch for WBA stock?

Short-term traders should watch the intraday band around $11.98, the 50-day average $11.66, and year high $13.25. Meyka AI’s 12-month model projects $14.50, a model-based figure and not a guarantee.

Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.